Nifedipine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Nifedipine: From Hypertension/Angina to Migraine with Brainstem Aura
One-Sentence Summary
Nifedipine is a dihydropyridine calcium channel blocker (CCB), a drug class established for treating hypertension and angina pectoris. The TxGNN model predicts it may be effective for migraine with brainstem aura, but this signal is currently supported by 0 clinical trials and only 2 publications — one of which is a controlled study reporting nifedipine was not effective as abortive therapy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension / Angina pectoris (general dihydropyridine CCB indication — no drug-specific record in this evidence pack) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 92.63% |
| Evidence Level | L4 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for nifedipine is not available in this evidence pack. Based on general pharmacological knowledge, nifedipine is a dihydropyridine calcium channel blocker; its efficacy in hypertension and angina is well established, and mechanistically calcium channel blockade could theoretically reduce vasospasm and cortical spreading depression (CSD)-related vascular events implicated in migraine pathophysiology.
However, the evidence pack’s own rationale for this specific candidate flags an important limitation: the mechanistic link is drawn from general migraine pathophysiology, not from any mechanism study specific to the brainstem aura (basilar-type) subtype — the supporting evidence is extrapolated from broader migraine research rather than targeted studies.
Notably, a related but broader candidate in this pack — “migraine disorder” (rank 2, score 91.80%, evidence level L2) — has a much larger evidence base (2 clinical trials, 20+ publications, several RCTs). Even within that larger body of evidence, nifedipine’s efficacy for migraine prophylaxis is inconsistent across studies and generally considered inferior to first-line agents such as flunarizine or beta-blockers. This broader context reinforces caution in interpreting the top-ranked, narrower “brainstem aura” prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1423566 | 1992 | RCT | Cephalalgia | Double-blind study of nifedipine as abortive treatment for acute migraine-with-aura attacks; nifedipine increased headache intensity compared with vehicle — concluded not useful as abortive therapy |
| 1353873 | 1992 | Review | Pathologie-biologie | Review of calcium antagonists (verapamil, diltiazem, nifedipine) for migraine prophylaxis; effectiveness of nifedipine cannot be considered firmly demonstrated given trial design limitations |
Australia Market Information
Nifedipine currently has no ARTG entries recorded in this evidence pack (market status: Not Marketed, 0 licenses). No product-specific Australian market information is available.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked predicted indication (migraine with brainstem aura) is supported only by mechanism-level extrapolation (L4) and no dedicated clinical trials; the only directly relevant RCT identified reported nifedipine was not effective and worsened headache intensity.
- A blocking data gap exists for TFDA/TGA product warnings and contraindications (DG001), which prevents even an initial (S1) safety assessment.
- The drug is not currently marketed or registered in Australia (0 ARTG entries), adding regulatory uncertainty on top of the weak efficacy signal.
To proceed, the following is needed:
- TGA-approved Product Information (warnings, contraindications) — required to clear the blocking safety gap before any further evaluation
- Drug-specific mechanism of action (MOA) data from DrugBank or equivalent source
- If pursuing the migraine indication further, consider redirecting research focus to the broader “migraine disorder” candidate (rank 2), which has a larger evidence base, while still weighing its documented inconsistent efficacy versus first-line prophylactic agents
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.